| Rhode Island Post Acute Medical Services 1 Pc | |
|
161 Post Rd Westerly RI 02891-2673 | |
| (865) 693-1000 | |
| Not Available |
| Full Name | Rhode Island Post Acute Medical Services 1 Pc |
|---|---|
| Speciality | Psychologist |
| Location | 161 Post Rd, Westerly, Rhode Island |
| Authorized Official Name and Position | David Istvan Holtzclaw (PRESIDENT) |
| Authorized Official Contact | 9545841000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Rhode Island Post Acute Medical Services 1 Pc 265 Brookview Centre Way Ste 400 Knoxville TN 37919-4052 Ph: (865) 693-1000 | Rhode Island Post Acute Medical Services 1 Pc 161 Post Rd Westerly RI 02891-2673 Ph: (865) 693-1000 |
| NPI Number | 1134658966 |
|---|---|
| Provider Enumeration Date | 06/06/2017 |
| Last Update Date | 11/27/2023 |
| Certification Date | 11/27/2023 |
| Medicare PECOS PAC ID | 9133493786 |
|---|---|
| Medicare Enrollment ID | O20170920000893 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134658966 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Secondary |
| 103TC0700X | Psychologist - Clinical | (* (Not Available)) | Primary |
| Provider Name | Kara Marie Kirker |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1548453145 PECOS PAC ID: 8527156264 Enrollment ID: I20071114000339 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Kenneth W Donovan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669447207 PECOS PAC ID: 4981653714 Enrollment ID: I20080318000712 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Carmine R Crispino |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861467367 PECOS PAC ID: 7911996426 Enrollment ID: I20080410000658 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Ingrid M Feder |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1609872845 PECOS PAC ID: 3274580709 Enrollment ID: I20090228000044 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Betsy L Moody |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1811036239 PECOS PAC ID: 0648259150 Enrollment ID: I20090508000205 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Edgar A Pollak |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629100920 PECOS PAC ID: 9032210331 Enrollment ID: I20100104000325 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Brandi P Cotton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033363601 PECOS PAC ID: 1658418322 Enrollment ID: I20110518000571 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Celina L Adams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780948596 PECOS PAC ID: 1052561982 Enrollment ID: I20121030000265 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Steven Lu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1568460186 PECOS PAC ID: 1658314091 Enrollment ID: I20141120001364 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Nabila K Mazumder |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033509567 PECOS PAC ID: 4880986579 Enrollment ID: I20160718001162 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Patricia F Varma |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407255375 PECOS PAC ID: 6103148820 Enrollment ID: I20160901002286 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Marjan Ul Mujib |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1982958328 PECOS PAC ID: 7810283074 Enrollment ID: I20161214001557 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Dianne E Seidell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962681403 PECOS PAC ID: 6204900046 Enrollment ID: I20161219001921 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Tiffany Lynne Rhodes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083028716 PECOS PAC ID: 0941428742 Enrollment ID: I20170331001070 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Paula Renzi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730414293 PECOS PAC ID: 6103012372 Enrollment ID: I20170727002488 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Janine Brooks |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386178093 PECOS PAC ID: 3577835560 Enrollment ID: I20171011002202 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Marian Nicole Sarosi |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1073690517 PECOS PAC ID: 3173419769 Enrollment ID: I20180416002487 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Debra L Furtado |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609346741 PECOS PAC ID: 7416298773 Enrollment ID: I20190415001192 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Joseph Alessandro |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447285986 PECOS PAC ID: 3375437940 Enrollment ID: I20190424002510 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Yardley Brice |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043635477 PECOS PAC ID: 8921337999 Enrollment ID: I20190917002128 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Sarah M Gamache |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598327603 PECOS PAC ID: 8527399328 Enrollment ID: I20191009001128 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Suleiman A Halaibeh |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1366670598 PECOS PAC ID: 8628403730 Enrollment ID: I20200120000313 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Alin O Bortan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154545754 PECOS PAC ID: 1355487950 Enrollment ID: I20200807002416 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Robin Allister |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720374036 PECOS PAC ID: 8527289040 Enrollment ID: I20201014003192 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Elizabeth Q Johnston |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689960288 PECOS PAC ID: 6002086915 Enrollment ID: I20201026002756 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Carissa M Kelly |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821307646 PECOS PAC ID: 2264627132 Enrollment ID: I20210520001931 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Fred Yeo |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881686616 PECOS PAC ID: 0244641660 Enrollment ID: I20221206002097 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Trish Bellinger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659377885 PECOS PAC ID: 4587604095 Enrollment ID: I20230301001320 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Bulent Ozcakar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174935894 PECOS PAC ID: 5597057190 Enrollment ID: I20230927001069 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
| Provider Name | Michelle Viveiros |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720448533 PECOS PAC ID: 2961791603 Enrollment ID: I20231030002090 |
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
News Archive
Reuters reports that "President Barack Obama's drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators - three Democrats and four Republicans - issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
The French health authority has revealed that it is rejecting half of all NeeS (non-eCTD electronic submissions) dossiers because they have been poorly formatted and do not meet basic validation standards. This is costing pharmaceutical companies time and money, as they re-work the submission format, and incur delays in getting their submissions reviewed and approved. Two-thirds of all electronic submissions to AFSSAPS currently are in the NeeS format.
Del Global Technologies Corp. today announced financial results for its fiscal 2010 fourth quarter and year ended July 31, 2010.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 7 days ago
Take Care Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 193 Canal St, Westerly, RI 02891 Phone: 401-500-5458 | |
True Self Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 21 Canal St Ste 2, Westerly, RI 02891 Phone: 401-932-0160 | |
Jason T Cerro, Lpc Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 14 Fieldstone Way, Westerly, RI 02891 Phone: 401-524-5938 | |
Leinhaas & Leinhaas Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 11 Wells St, Suite #8, Westerly, RI 02891 Phone: 401-596-4769 Fax: 401-596-4276 | |
Coastal Counseling And Recovery Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 21 Canal St Ste 201, Westerly, RI 02891 Phone: 401-742-6802 | |
Cornerstone Counseling Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 10 Hillview Dr, Westerly, RI 02891 Phone: 401-596-8800 Fax: 401-315-8831 |